TNF Inhibitor denied for failing step therapy by Anthem Blue Cross?

Anthem CA uses CarelonRx PBM. Adalimumab biosimilar preferred. CA SB 853 protects against non-medical switching for stable patients.

Cite CA SB 853 (Continuity of Care) — protects stable patients from non-medical switches. Cite CG-DRUG-64 by name. CarelonRx exception process.

## Why Anthem Blue Cross Denies TNF Inhibitors Under Step Therapy

Anthem Blue Cross uses step-therapy (also called "fail-first") requirements for TNF inhibitors, meaning the plan requires documented evidence that one or more lower-cost or preferred agents were tried and did not work before it will authorize a biologic. A step-therapy denial means either the documentation of prior steps was missing, was insufficient to meet Anthem's criteria, or the prescriber did not submit a step-therapy exception demonstrating why the required steps cannot be completed safely for this patient.

Step-therapy denials are among the most frequently overturned on appeal, because the clinical record often contains the necessary documentation — it simply was not organized in a way that maps to Anthem's specific criteria. A well-structured appeal can make the difference.

## Federal Appeal Framework

• Step-therapy exception (first path): Most states and ERISA regulations provide a step-therapy exception process. Your prescriber can request an exception by documenting that the required prior step is contraindicated, previously failed, or clinically inappropriate.
• Internal appeal (ERISA §503 / ACA §2719): File within the deadline on your denial letter. Request the exact step-therapy criteria Anthem applied. Submit a full-and-fair review with complete documentation of prior steps.
• External independent review: Available after internal exhaustion on ACA-compliant plans. The window is generally up to approximately four months from final internal denial. IRO decisions are binding on Anthem.
• Expedited review: If the standard timeline creates a serious health risk.
• State step-therapy laws: Many states have enacted step-therapy protection laws that limit how many steps can be required and mandate exception timelines. Verify whether your state's law applies to your plan type.

## Documentation to Gather

1. Prior therapy log — for each required step agent, document: drug name, start date, end date, dose adjustments (per chart), and the clinical reason for discontinuation (inadequate response, adverse event, or prescriber-documented exception basis). 2. Diagnosis and severity — specialist notes, objective clinical findings, and disease-activity assessments confirming the diagnosis and severity level. 3. Why the step cannot be completed — if a required prior step was not taken, the prescriber must document the clinical basis: prior failure on that agent for another condition, a documented contraindication per their clinical judgment, or other individualized reason. 4. Prescriber medical-necessity letter — a letter mapping each Anthem step requirement to a specific chart entry, or explaining the clinical basis for skipping a required step. 5. Anthem's step-therapy policy — retrieve the current published policy to understand exactly which agents are required steps and in what order.

## Criteria-Mapping Structure

| Anthem Step-Therapy Requirement | Chart Evidence or Exception Basis | |---|---| | Step 1: [Drug class/agent from Anthem policy] | [Date tried / date started + outcome OR exception rationale] | | Step 2: [Next required agent] | [Same format] | | Exception criterion (if applicable) | [Clinical basis from chart] |

Reference the FDA-approved prescribing label for the requested TNF inhibitor and the applicable guideline organization's (e.g., ACR, AGA, AAD) treatment algorithm when explaining why this agent is the appropriate next step. Never rely on specific numeric thresholds or dosing details from memory.